First Trust Advisors LP Trims Stake in AbbVie Inc. $ABBV

First Trust Advisors LP reduced its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 43.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,502,221 shares of the company's stock after selling 1,155,532 shares during the quarter. First Trust Advisors LP owned 0.09% of AbbVie worth $278,842,000 as of its most recent SEC filing.

• HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

A number of other hedge funds also recently added to or reduced their stakes in ABBV. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie in the 2nd quarter valued at about $25,000. TD Capital Management LLC increased its holdings in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after buying an additional 58 shares during the period. Spurstone Advisory Services LLC purchased a new position in AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new position in AbbVie in the second quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. lifted its holdings in AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company's stock worth $40,000 after buying an additional 173 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Trading Up 2.6%

Shares of ABBV stock opened at $230.32 on Thursday. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company's 50-day moving average price is $227.98 and its 200-day moving average price is $207.76. The stock has a market cap of $407.06 billion, a price-to-earnings ratio of 174.48, a PEG ratio of 1.22 and a beta of 0.36.

• Healthcare Rotation Underway: 3 Stocks Leading the Charge

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is a boost from AbbVie's previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie's payout ratio is currently 524.24%.

Analyst Ratings Changes

• ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat

ABBV has been the topic of a number of recent research reports. Raymond James Financial set a $256.00 price objective on AbbVie in a research report on Monday, November 3rd. Hsbc Global Res lowered shares of AbbVie from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 1st. UBS Group raised their price objective on AbbVie from $195.00 to $220.00 and gave the stock a "neutral" rating in a research report on Friday, November 7th. Scotiabank initiated coverage on AbbVie in a research report on Thursday, November 13th. They issued a "sector outperform" rating and a $280.00 target price on the stock. Finally, Wells Fargo & Company increased their price target on AbbVie from $240.00 to $260.00 and gave the stock an "overweight" rating in a research report on Friday, September 12th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $241.85.

Get Our Latest Report on ABBV

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Featured Stories

• Five stocks we like better than AbbVie
• How to Evaluate a Stock Before Buying
• 3 Stocks Poised to Benefit From Google’s AI Breakthough
• 3 REITs to Buy and Hold for the Long Term
• Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
• How to Effectively Use the MarketBeat Ratings Screener
• 3 Stocks You’ll Wish You Bought Before 2026

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here